New Peptide Linker Makes Cancer-Targeting Antibody Drug More Stable and Safer
A novel RKAA-peptide linker technology creates a more stable CD79b-targeting antibody-drug conjugate than FDA-approved polatuzumab vedotin.
Quick Facts
What This Study Found
A novel RKAA-peptide linker creates a more stable CD79b-ADC than polatuzumab vedotin, potentially widening the therapeutic window.
Key Numbers
Drug-to-antibody ratio of 2; equal efficacy at half payload dose vs polatuzumab vedotin; stable in mouse, cynomolgus, and human sera.
How They Did This
Preclinical comparison of RKAA-peptide linked ADC vs. FDA-approved polatuzumab vedotin for stability, efficacy, and safety.
Why This Research Matters
Better ADC stability means less drug leaks into healthy tissue, potentially reducing severe side effects while maintaining cancer-killing power.
The Bigger Picture
Next-generation ADC linker technologies could make targeted cancer therapy both more effective and less toxic.
What This Study Doesn't Tell Us
Preclinical study — human clinical trial data needed to confirm safety and efficacy advantages.
Questions This Raises
- ?Can the RKAA linker be applied to other ADC targets beyond CD79b?
- ?Does improved stability translate to better clinical outcomes?
Trust & Context
- Key Stat:
- Improved stability RKAA-peptide linked ADC shows better circulatory stability than FDA-approved polatuzumab vedotin
- Evidence Grade:
- Preclinical comparison study — demonstrates improved pharmacological properties but requires clinical validation.
- Study Age:
- Published in 2025, advancing next-generation ADC technology.
- Original Title:
- Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC.
- Published In:
- Molecular cancer therapeutics, 24(6), 803-815 (2025)
- Authors:
- Probst, Philipp, Attinger-Toller, Isabella, Bertrand, Romain, Stark, Ramona, Santimaria, Roger, Schlereth, Bernd, Grabulovski, Dragan, Spycher, Philipp René
- Database ID:
- RPEP-13113
Evidence Hierarchy
Frequently Asked Questions
What is an antibody-drug conjugate?
A targeted cancer therapy that attaches a chemotherapy drug to an antibody that specifically finds cancer cells, delivering the drug directly to tumors.
Why does the linker matter in ADCs?
The linker holds the drug onto the antibody — if it is unstable, the drug releases prematurely into the bloodstream, causing toxicity to healthy tissue.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13113APA
Probst, Philipp; Attinger-Toller, Isabella; Bertrand, Romain; Stark, Ramona; Santimaria, Roger; Schlereth, Bernd; Grabulovski, Dragan; Spycher, Philipp René. (2025). Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC.. Molecular cancer therapeutics, 24(6), 803-815. https://doi.org/10.1158/1535-7163.MCT-24-0983
MLA
Probst, Philipp, et al. "Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC.." Molecular cancer therapeutics, 2025. https://doi.org/10.1158/1535-7163.MCT-24-0983
RethinkPeptides
RethinkPeptides Research Database. "Broadening the Therapeutic Window of ADCs Using Site-Specifi..." RPEP-13113. Retrieved from https://rethinkpeptides.com/research/probst-2025-broadening-the-therapeutic-window
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.